Navigation Links
Essure Procedure Now Covered by Medicaid in California
Date:5/14/2008

MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- Conceptus, Inc. (Nasdaq: CPTS) developer of the Essure(R) procedure, the first and only non-incisional permanent birth control method available, today reported that Medi-Cal, California's state fee-for-service Medicaid program, is now covering the Essure procedure. Low-income or disabled women in California now have a safe and effective permanent female birth control option that does not require the general anesthesia, incisions or long recovery period of traditional tubal ligation.

"We are very happy that Medi-Cal has completed its review of the safety and efficacy of the Essure device and has established coverage for this procedure," said California Assembly Speaker pro Tem Sally Lieber. "This is a great day for the women of California covered by Medicaid, who will now be able to avoid the risks and long recovery times associated with traditional tubal ligation surgery."

The Essure procedure is now a covered procedure for Medi-Cal beneficiaries that are 21 years of age or older. Physicians may perform the Essure procedure in the physician's office, the ambulatory surgery center or the hospital outpatient department. Medi-Cal is expected to pay $2,282 as a global fee for an in-office procedure. This coverage decision impacts approximately 3.8 million Californians.

Coverage of the Essure procedure enables state Medicaid programs to provide a safe, convenient and economical choice for preventing pregnancies. In addition, the shorter recovery time-typically one day as compared with four to six days for the traditional laparoscopic procedure-means a faster return to work or home responsibilities. California joins 45 other states now covering the Essure procedure for women enrolled in Medicaid. Conceptus has yet to receive Medicaid decisions for the Essure procedure in Arizona, Nebraska, North Dakota, Utah and Washington.

"We continue to provide compelling information on the costs and benefits of the Essure procedure to those few remaining state Medicaid programs that have not given a coverage decision, and to lobby for improved payment in those states with poor reimbursement," commented Mark Sieczkarek, president and chief executive officer of Conceptus. "This positive coverage decision from Medi-Cal is an important step in our efforts to make Essure available to women from all socioeconomic backgrounds."

About the Essure Procedure

The Essure procedure, approved by the FDA in 2002, is a permanent birth control procedure that replaces tubal ligation for women. In the comfort of a physician's office and in about 10 minutes, the soft micro-inserts are placed into the Fallopian tubes through the cervix eliminating the need for incisions. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the Fallopian tubes.

The Essure confirmation test is performed three months after the procedure to confirm that the micro-inserts are in the correct location, the tubes are blocked and that the woman can discontinue temporary birth control. The Essure procedure is 99.80% effective and is the first and only FDA approved female sterilization procedure to have zero pregnancies in clinical trials.

About Conceptus

Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.

Additional information about the Essure procedure is available at http://www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at http://www.conceptus.com or by calling 1-877-ESSURE2.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Discussions regarding the continued availability of Medicaid coverage, and the Company's ability to obtain Medicaid coverage from additional states, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors such as strategic planning decisions by management, re-allocation of internal resources, decisions by insurance companies, scientific advances by third parties, and introduction of competitive products, as well as those factors set forth in the Company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and other filings with the Securities and Exchange Commission.

Contact Information:

Ashley Biever

310-577-7870 x 111

ashley.biever@fischerhealth.com


'/>"/>
SOURCE Conceptus, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Aspirin at Bedtime Lowers Blood Pressure
2. High Blood Pressure, Cholesterol Associated With Eye Disease
3. High Blood Pressure Still Slipping Past Doctors
4. Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life, Including Pregnancy
5. Double duty: Loss of protective heart failure protein causes high blood pressure
6. Simple Steps Lead to Better Blood Pressure Control
7. Blood pressure killing the worlds workers while banks and drug firms stand idle
8. High blood pressure still sneaking past doctors, Stanford study shows
9. Study Reveals Women Feeling Growing Financial Pressures on Family Life
10. High Blood Pressure May Be Buffer Against Headaches
11. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... NJ (PRWEB) , ... December 08, 2016 , ... CURE ... cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to ... making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... 08, 2016 , ... Today’s patients are encouraged to be ... SIGVARIS has created a new line of anti-embolism stockings to help prevent a ... benefits of graduated compression when transitioning from recovery to early rehabilitation. , The ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research and Markets ... Report" report to their offering. ... This report analyzes the worldwide markets for ... US, Canada , Japan , ... , and Rest of World. Annual estimates and forecasts are provided ...
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX , ... Nationwide Children,s Hospital signed a membership agreement ... the development of new cures. The ... over 57 million patients globally, biopharmaceutical companies and ... to improve protocol design, site selection, patient recruitment, ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology: